Tyco International (TYC ) is splitting into three companies: ADT North America Residential; Flow Control; and Commercial Fire and Security. The company said, ‘œAll three companies will have industry-leading positions in large and fragmented industries and enhanced capabilities to serve their distinct customers ……….Importantly, the new standalone
Entering a limit order at $171.52 on a 5% tranche of GLD to take partial profits.
There are lots of rumors floating around that United Technologies (UTX) is looking to make a major acquisition. The potential targets are Tyco (TYC), Goodrich (GR), Honeywell (HON) and Rockwell Collins (COL). In our opinion, Honeywell and Tyco are the least likely targets, Goodrich is the best target. Since
Our proprietary algorithms continue to show that smart money is selling Research In Motion (RIMM) on all up moves. Please earlier posts for more details.
An analysis of 30 years of data in 15 emerging markets reveals that big money in the emerging markets is consistently made by paying attention to geopolitical events. The key to profits lies in recognizing change before the crowd using a proven method such as the ZYX Change Method. The
The following post on St Joe Company (JOE ) appeared this morning in the Real Time Feed of the ZYX Buy Change Alert. Joe has entered into an agreement with Fairholme, its largest shareholder, permitting it to acquire beneficial ownership of up to 50% of outstanding common stock. Joe, the
Research in Motion (RIMM) has moved up from its morning lows. Our Smart MoneyIndicator shows that smart money is selling Research In Motion into the strength.
Readers may want to start from my previous article on Research In Motion titled What Is The True Value Of Research In Motion? In the article I described various scenarios for Research In Motion (RIMM). One of the scenarios I described was for Research in Motion to continue on its
It is time to take profits on Acorda Therapeutics (ACOR). Consider taking profits on the entire position of Acorda Therapeutics right here at $23.08. Ampyra, the drug that has caused most excitement in Acora Therapeutics, is not proving to be a very good drug as we had predicted.
Vivus (VVUS ) shares have moved up strongly on the news that FDA has agreed to an early re-submission of the QNEXA NDA for the treatment of obesity. The road is not all clear for Vivus. There are still major issues that need to be resolved by Vivus